Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Search type
Keyword
Author
Edition
European
US
Neurology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Interviews
Society updates
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Advancing Alzheimer’s Disease Treatment: Interview with Jeffrey L. Cummings
5
Mins
October 2026
The most influential change has been the evolution of biomarkers, beginning around 2012 with the approval of amyloid PET, so that we…
Read more
5
Mins
23 Oct 2026
Advancing Alzheimer’s Disease Treatment: Interview with Jeffrey L. Cummings
The most influential change has been the evolution of biomarkers, beginning around 2012 with the approval of amyloid PET, so that we…
11
Mins
7 Sep 2026
Interview: Ari Zimran
It is indeed remarkable to realise that it is now exactly 40 years since I joined the late Professor. Ernest Beutler as a research fellow…
5
Mins
2 Sep 2026
The Evolving Landscape of Friedreich’s Ataxia – David R. Lynch
Your career has spanned a period of major transformation in our understanding of Friedreich’s ataxia (FRDA)…
5
Mins
28 Aug 2026
Understanding VNS MOA in Epilepsy
Epilepsy is a chronic neurological disorder characterised by recurrent, unprovoked seizures that can significantly affect morbidity…
5
Mins
11 Aug 2026
Migraine with Aura: Does It Require Different Treatment?
Migraine has two main forms: migraine with aura (MwA) and migraine without aura (MwoA).1 The former is less common and only affects…
5
Mins
11 Aug 2026
SUDEP: From Prediction to Prevention
Sudden unexpected death in epilepsy (SUDEP) remains the leading directly epilepsy-related cause of death. It is predominantly nocturnal…
4
Mins
11 Aug 2026
The Urgent Need for a Parkinson’s Disease Patient Support Group in Latvia
Across Europe, people living with Parkinson’s disease (PD) increasingly benefit from strong patient advocacy organisations and community…
12
Mins
11 Aug 2026
Rethinking Cognitive Screening in Multiple Sclerosis
Few health concerns carry greater psychological weight than the possibility of cognitive decline. Surveys consistently identify loss of…
Loading posts...
1
2
3
…
28
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View